Patent · US Active

Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use

US12384851B2 · kind B2 · utility

0Cited by

67References

30Claims

0Family size

Assignee

Dragonfly Therapeutics, Inc. · US

Inventors

Mitchell Bigelow · Cambridge, US
Gregory P. Chang · Medford, US
Ann F. Cheung · Lincoln, US
Asya Grinberg · Lexington, US
William Haney · Wayland, US
Nicolai Wagtmann · Concord, US
Bradley M. Lunde · Lebanon, US
Bianka Prinz · Lebanon, US
Ronnie Wei · Weston, US
Daniel Fallon · Winchester, US
Steven O'Neil · Wayland, US

Key dates

Filing date	Aug 8, 2019
Grant date	Aug 12, 2025
Priority date	—
Expiry date	Sep 14, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.